Novo Integrated Sciences’ IoNovo for Kids Pure Iodine Oral Spray Granted Natural Product Number (NPN) by Health Canada

Rhea-AI Summary

Novo Integrated Sciences (NASDAQ: NVOS) announced that its subsidiary, Novo Healthnet Limited, received a Natural Product Number (NPN) from Health Canada for its IoNovo for Kids pure iodine oral spray. This product is the first of its kind designed specifically for children under 13, ensuring safety and efficacy. Iodine is recognized for its health benefits, and this innovative oral spray provides a convenient way for parents to enhance their children's biosecurity. Novo continues to focus on developing health and wellness solutions through its multidisciplinary healthcare ecosystem.

Positive

• Received Natural Product Number (NPN) from Health Canada for IoNovo for Kids.
• First iodine oral spray specifically designed for children under 13, providing safety and efficacy.
• Innovative product enhances biosecurity for children.
• Focus on multidisciplinary healthcare ecosystem for health and wellness solutions.

Negative

• None.

IoNovo for Kids is the first pure iodine oral spray designed for kids proven to be safe and effective

BELLEVUE, Wash.--(BUSINESS WIRE)-- Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem with multiple patient and consumer touchpoints for services and product innovation, today announced that its wholly owned subsidiary, Novo Healthnet Limited, has been granted a Natural Product Number (NPN) by Health Canada for its IoNovo for Kids pure iodine oral spray branded product line. An NPN is a product license assessed and granted by Health Canada Natural Health Products determined to be safe, effective, of high quality, and eligible for sale in Canada.

Robert Mattacchione, Novo’s CEO and Board Chairman, commented, “For decades, the global medical community has recognized Iodine as an aid for a healthy metabolism as well as one of nature’s finest killers in the microbial world. Our IoNovo Iodine for Kids product is an aqueous iodine dosed in a safe ingestible form, as a simple oral spray, for maximum bio-availability. Understanding children are highly mobile and social exposing them to harmful pathogens from the microbial world, we designed IoNovo for Kids, specifically for children under 13 years of age, to deliver micro-dose amounts per application. For the first time the child and their parents can simply spray iodine throughout the day providing a next level of personal biosecurity.”

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

• First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
• Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
• Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient first platforms.

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com. For more information on Novo Healthnet Limited, Novo’s wholly owned subsidiary, please visit www.novohealthnet.com

Twitter, LinkedIn, Facebook, Instagram, YouTube

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," “intend,” "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220218005057/en/

Chris David, COO-President

Novo Integrated Sciences, Inc.

chris.david@novointegrated.com

(888) 512-1195

Source: Novo Integrated Sciences, Inc.

FAQ

What is the significance of the NPN granted to NVOS for IoNovo for Kids?

The NPN indicates that IoNovo for Kids has been assessed by Health Canada for safety and effectiveness, allowing it to be sold in Canada.

When was the NPN for IoNovo for Kids announced?

The NPN was announced in a press release by Novo Integrated Sciences on a recent date, indicating the company's ongoing product development.

What are the health benefits of IoNovo for Kids?

IoNovo for Kids is based on iodine, which is known to support healthy metabolism and provide antimicrobial properties.

Is IoNovo for Kids designed for any specific age group?

Yes, IoNovo for Kids is specifically designed for children under 13 years of age.

How does IoNovo for Kids enhance personal biosecurity?

The oral spray allows for easy and safe dosing of iodine throughout the day to help protect children from harmful pathogens.